KPIs & Operating Metrics(New)
Growth Metrics

Johnson & Johnson (JNJ) Total Liabilities (2009 - 2026)

Johnson & Johnson recorded quarterly Total Liabilities of $119.7 billion in Q1 2026, up 1.74% quarter-over-quarter from $117.7 billion in Q4 2025, and up 3.59% year-over-year from $115.6 billion in Q1 2025.

Johnson & Johnson's Total Liabilities history runs 18 years deep, the most recent figure standing at $119.7 billion for Q1 2026.

  • In Q1 2026, Total Liabilities rose 3.59% year-over-year to $119.7 billion; the TTM figure through Mar 2026 stood at $119.7 billion (up 3.59% YoY), while the FY2025 annual figure was $117.7 billion, up 8.33% from the prior year.
  • Total Liabilities came in at $119.7 billion for Q1 2026 at Johnson & Johnson, up from $117.7 billion in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $125.1 billion in Q2 2023 to a low of $94.8 billion in Q4 2023.
  • A 5-year average of $109.3 billion and a median of $109.1 billion in 2024 frame the typical range for Total Liabilities.
  • Across the five-year window, Total Liabilities rose 20.7% in 2023 and slipped 18.51% in 2024, its largest moves.
  • Johnson & Johnson's Total Liabilities stood at $100.5 billion in 2022, then declined by 1.73% to $98.8 billion in 2023, then increased by 9.95% to $108.6 billion in 2024, then increased by 8.33% to $117.7 billion in 2025, then gained by 1.74% to $119.7 billion in 2026.
  • According to Business Quant data, Total Liabilities over the past three periods registered $119.7 billion, $117.7 billion, and $113.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Liabilities (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 85.38 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 119.71 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 143.08 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn 82.75 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn 83.31 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 32.76 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 117.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 66.37 Bn
10 Gsk 88.34 Bn 83.66 Bn - 60.07 Bn

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 119.71 Bn
Dec 28, 2025 117.67 Bn
Sep 28, 2025 113.54 Bn
Jun 29, 2025 114.92 Bn
Mar 30, 2025 115.56 Bn
Dec 29, 2024 108.61 Bn
Sep 29, 2024 108.13 Bn
Jun 30, 2024 109.55 Bn
Mar 31, 2024 101.95 Bn
Dec 31, 2023 98.78 Bn
Oct 1, 2023 94.83 Bn
Jul 2, 2023 115.28 Bn
Apr 2, 2023 125.10 Bn
Jan 1, 2023 110.57 Bn
Oct 2, 2022 100.53 Bn
Jul 3, 2022 101.37 Bn
Apr 3, 2022 103.65 Bn
Jan 2, 2022 108.00 Bn
Oct 3, 2021 108.96 Bn
Jul 4, 2021 106.86 Bn
Apr 4, 2021 106.72 Bn
Jan 3, 2021 111.62 Bn
Sep 27, 2020 106.22 Bn
Jun 28, 2020 95.40 Bn
Mar 29, 2020 93.72 Bn
Dec 29, 2019 98.26 Bn
Sep 29, 2019 97.31 Bn
Jun 30, 2019 94.33 Bn
Mar 31, 2019 91.07 Bn
Dec 30, 2018 93.20 Bn
Sep 30, 2018 91.08 Bn
Jul 1, 2018 92.48 Bn
Apr 1, 2018 93.37 Bn
Dec 31, 2017 97.14 Bn
Oct 1, 2017 81.68 Bn
Jul 2, 2017 80.89 Bn
Apr 2, 2017 74.58 Bn
Jan 1, 2017 70.79 Bn
Oct 2, 2016 67.60 Bn
Jul 3, 2016 67.34 Bn
Apr 3, 2016 63.58 Bn
Jan 3, 2016 62.26 Bn
Sep 27, 2015 61.71 Bn
Jun 28, 2015 60.91 Bn
Mar 29, 2015 60.71 Bn
Dec 28, 2014 60.61 Bn
Sep 28, 2014 55.51 Bn
Jun 29, 2014 57.15 Bn
Mar 30, 2014 56.75 Bn
Dec 29, 2013 58.63 Bn
Sep 29, 2013 57.13 Bn
Jun 30, 2013 54.66 Bn
Mar 31, 2013 54.68 Bn
Dec 30, 2012 56.52 Bn
Sep 30, 2012 55.19 Bn
Jul 1, 2012 55.32 Bn
Apr 1, 2012 54.83 Bn
Jan 1, 2012 56.56 Bn
Oct 2, 2011 50.29 Bn
Jul 3, 2011 49.98 Bn
Apr 3, 2011 48.29 Bn
Jan 2, 2011 46.33 Bn
Oct 3, 2010 40.96 Bn
Jul 4, 2010 39.45 Bn
Apr 4, 2010 40.53 Bn
Jan 3, 2010 44.09 Bn
Sep 27, 2009 41.17 Bn
Jun 28, 2009 41.19 Bn